These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 24277021

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Pharmacokinetic and Pharmacodynamic Target Attainment in Adult and Pediatric Patients Following Administration of Ceftaroline Fosamil as a 5-Minute Infusion.
    Riccobene TA, Carrothers TJ, Knebel W, Raber S, Chan PLS.
    Clin Pharmacol Drug Dev; 2021 Apr; 10(4):420-427. PubMed ID: 33465279
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Ceftaroline efficacy against high-MIC clinical Staphylococcus aureus isolates in an in vitro hollow-fibre infection model.
    Singh R, Almutairi M, Alm RA, Lahiri SD, San Martin M, Chen A, Ambler JE.
    J Antimicrob Chemother; 2017 Oct 01; 72(10):2796-2803. PubMed ID: 29091195
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Population Pharmacokinetic Modeling and Probability of Target Attainment Analyses in Asian Patients With Community-Acquired Pneumonia Treated With Ceftaroline Fosamil.
    Li J, Das S, Zhou D, Al-Huniti N.
    Clin Pharmacol Drug Dev; 2019 Jul 01; 8(5):682-694. PubMed ID: 31044546
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Single- and Repeated-Dose Pharmacokinetics of Ceftaroline in Plasma and Soft Tissues of Healthy Volunteers for Two Different Dosing Regimens of Ceftaroline Fosamil.
    Matzneller P, Lackner E, Lagler H, Wulkersdorfer B, Österreicher Z, Zeitlinger M.
    Antimicrob Agents Chemother; 2016 Jun 01; 60(6):3617-25. PubMed ID: 27044549
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Evaluation of ceftaroline activity versus ceftriaxone against clinical isolates of Streptococcus pneumoniae with various susceptibilities to cephalosporins in an in vitro pharmacokinetic/pharmacodynamic model.
    Steed ME, Vidaillac C, Winterfield P, Biek D, Rybak MJ.
    Antimicrob Agents Chemother; 2012 May 01; 56(5):2691-5. PubMed ID: 22354289
    [Abstract] [Full Text] [Related]

  • 16. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects.
    Lodise TP, Pypstra R, Kahn JB, Murthy BP, Kimko HC, Bush K, Noel GJ, Drusano GL.
    Antimicrob Agents Chemother; 2007 Jul 01; 51(7):2378-87. PubMed ID: 17387149
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Impact of Key Components of Intensified Ceftaroline Dosing on Pharmacokinetic/Pharmacodynamic Target Attainment.
    Minichmayr IK, Wicha SG, Matzneller P, Kloft C, Zeitlinger M.
    Clin Pharmacokinet; 2024 Jan 01; 63(1):121-131. PubMed ID: 38007714
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.